Shona L Pfeiffer

Dr. Shona L Pfeiffer

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RRRana Raoof
Rana Raoof
Eva María Jiménez-MateosEva María Jiménez-Mateos
Eva María Jiménez-Mateos
SBSebastian Bauer
Sebastian Bauer
BTBjörn Tackenberg
Björn Tackenberg
FRFelix Rosenow
Felix Rosenow
Catherine MooneyCatherine Mooney
Catherine Mooney
There is a need for diagnostic biomarkers of epilepsy and status epilepticus to support clinical examination, electroencephalography and neuroimaging. Extracellular microRNAs may be potentially ideal biomarkers since some are expressed uniquely within specific brain regions and cell types. Cerebrospinal fluid offers a source of microRNA biomarkers with the advantage of being in close contact with the target tissue and sites of pathology. Here we profiled microRNA levels in cerebrospinal fluid from patients with temporal lobe epilepsy or status epilepticus, and compared findings to matched controls. Differential expression of 20 microRNAs was detected between patient groups and controls. A validation phase included an expanded cohort and samples from patients with other neurological diseases. This identified lower levels of miR-19b in temporal lobe epilepsy compared to controls, status epilepticus and other neurological diseases. Levels of miR-451a were higher in status epilepticus compared to other groups whereas miR-21-5p differed in status epilepticus compared to temporal lobe epilepsy but not to other neurological diseases. Targets of these microRNAs include proteins regulating neuronal death, tissue remodelling, gliosis and inflammation. The present study indicates cerebrospinal fluid contains microRNAs that can support differential diagnosis of temporal lobe epilepsy and status epilepticus from other neurological and non-neurological diseases.

28 January 2015 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
BDBeatrice D'ORsi
Beatrice D'ORsi
SKSeán M. Kilbride
Seán M. Kilbride
GCGang Chen
Gang Chen
SASergio Perez Alvarez
Sergio Perez Alvarez
HBHelena P. Bonner
Helena P. Bonner
Jochen PrehnJochen Prehn
Jochen Prehn
Excessive Ca2+entry during glutamate receptor overactivation (“excitotoxicity”) induces acute or delayed neuronal death. We report here that deficiency inbaxexerted broad neuroprotection against excitotoxic injury and oxygen/glucose deprivation in mouse neocortical neuron cultures and reduced infarct size, necrotic injury, and cerebral edema formation after middle cerebral artery occlusion in mice. Neuronal Ca2+and mitochondrial membrane potential (Δψm) analysis during excitotoxic injury revealed thatbax-deficient neurons showed significantly reduced Ca2+transients during the NMDA excitation period and did not exhibit the deregulation of Δψmthat was observed in their wild-type (WT) counterparts. Reintroduction ofbaxor abaxmutant incapable of proapoptotic oligomerization equally restored neuronal Ca2+dynamics during NMDA excitation, suggesting that Bax controlled Ca2+signaling independently of its role in apoptosis execution. Quantitative confocal imaging of intracellular ATP or mitochondrial Ca2+levels using FRET-based sensors indicated that the effects ofbaxdeficiency on Ca2+handling were not due to enhanced cellular bioenergetics or increased Ca2+uptake into mitochondria. We also observed that mitochondria isolated from WT orbax-deficient cells similarly underwent Ca2+-induced permeability transition. However, when Ca2+uptake into the sarco/endoplasmic reticulum was blocked with the Ca2+-ATPase inhibitor thapsigargin,bax-deficient neurons showed strongly elevated cytosolic Ca2+levels during NMDA excitation, suggesting that the ability of Bax to support dynamic ER Ca2+handling is critical for cell death signaling during periods of neuronal overexcitation.

20 April 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
BDBeatrice D'ORsi
Beatrice D'ORsi
Tobias Engel EngelTobias Engel Engel
Tobias Engel Engel
SPShona L Pfeiffer
Shona L Pfeiffer
SNSaheli Nandi
Saheli Nandi
TKThomas Kaufmann
Thomas Kaufmann
Jochen PrehnJochen Prehn
Jochen Prehn
Bok (Bcl-2-related ovarian killer) is a Bcl-2 family member that, because of its predicted structural homology to Bax and Bak, has been proposed to be a pro-apoptotic protein. In this study, we demonstrate that Bok is highly expressed in neurons of the mouse brain but thatbokwas not required for staurosporine-, proteasome inhibition-, or excitotoxicity-induced apoptosis of cultured cortical neurons. On the contrary, we found thatbok-deficient neurons were more sensitive to oxygen/glucose deprivation-induced injuryin vitroand seizure-induced neuronal injuryin vivo. Deletion ofbokalso increased staurosporine-, excitotoxicity-, and oxygen/glucose deprivation-induced cell death inbax-deficient neurons. Single-cell imaging demonstrated thatbok-deficient neurons failed to maintain their neuronal Ca2+homeostasis in response to an excitotoxic stimulus; this was accompanied by a prolonged deregulation of mitochondrial bioenergetics.bokdeficiency led to a specific reduction in neuronal Mcl-1 protein levels, and deregulation of both mitochondrial bioenergetics and Ca2+homeostasis was rescued by Mcl-1 overexpression. Detailed analysis of cell death pathways demonstrated the activation of poly ADP-ribose polymerase-dependent cell death inbok-deficient neurons. Collectively, our data demonstrate that Bok acts as a neuroprotective factor rather than a pro-death effector during Ca2+- and seizure-induced neuronal injuryin vitroandin vivo.SIGNIFICANCE STATEMENTBcl-2 proteins are essential regulators of the mitochondrial apoptosis pathway. The Bcl-2 protein Bok is highly expressed in the CNS. Because of its sequence similarity to Bax and Bak, Bok has long been considered part of the pro-apoptotic Bax-like subfamily, but no studies have yet been performed in neurons to test this hypothesis. Our study provides important new insights into the functional role of Bok during neuronal apoptosis and specifically in the setting of Ca2+- and seizure-mediated neuronal injury. We show that Bok controls neuronal Ca2+homeostasis and bioenergetics and, contrary to previous assumptions, exerts neuroprotective activitiesin vitroandin vivo. Our results demonstrate that Bok cannot be placed unambiguously into the Bax-like Bcl-2 subfamily of pro-apoptotic proteins.

31 May 2021 in Journal of Stroke
Verified
Journal Article
Open access
PDF file
JBJorin Bejleri
Jorin Bejleri
EJElisabeth Jirström
Elisabeth Jirström
PDPaul Donovan
Paul Donovan
DWDavid J. Williams
David J. Williams
SPShona L Pfeiffer
Shona L Pfeiffer
Background and Purpose Stroke is the second leading cause of death and disability worldwide and its diagnosis, and assessment of prognosis, remains challenging. There is a need for improved diagnostic and prognostic biomarkers. MicroRNAs (miRNAs) play important roles in the post-transcriptional regulation of gene expression and their secretion and remarkable stability in biofluids highlights their potential as sensitive biomarkers in the diagnosis and prognosis of acute stroke.Methods We carried out a systematic review to assess current evidence supporting the potential of miRNAs to act as unique diagnostic and prognostic biomarkers in blood samples collected from patients suffering acute stroke within 24 hours of symptoms onset.Results We identified 22 studies eligible for inclusion with 33 dysregulated miRNAs having diagnostic potential in the acute phase of the disease. We identified miR-16, miR-126, and miR-335 as having the highest sensitivity as diagnostic and prognostic biomarkers in acute ischaemic stroke and present original bioinformatic and pathway enrichment analysis of putative miRNA–target interactions.Conclusions miRNAs represent unique biomarkers which have a promising future in stroke diagnosis and prognosis. However, there is a need for more standardized and consistent methodology for the accurate interpretation and translation of miRNAs as novel specific and sensitive biomarkers into clinical practice.

22 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SPShona L Pfeiffer
Shona L Pfeiffer
BSBegoña Sánchez-Lechuga
Begoña Sánchez-Lechuga
PDPaul Donovan
Paul Donovan
LHLuise Halang
Luise Halang
JPJochen H. M. Prehn
Jochen H. M. Prehn
CLCristina López-Tinoco
Cristina López-Tinoco
Gestational Diabetes Mellitus (GDM) is characterised by insulin resistance accompanied by reduced beta-cell compensation to increased insulin demand, typically observed in the second and third trimester and associated with adverse pregnancy outcomes. There is a need for a biomarker that can accurately monitor status and predict outcome in GDM, reducing foetal-maternal morbidity and mortality risks. To this end, circulating microRNAs (miRNAs) present themselves as promising candidates, stably expressed in serum and known to play crucial roles in regulation of glucose metabolism. We analysed circulating miRNA profiles in a cohort of GDM patients (n = 31) and nondiabetic controls (n = 29) during the third trimester for miRNA associated with insulin-secretory defects and glucose homeostasis. We identified miR-330-3p as being significantly upregulated in lean women with GDM compared to nondiabetic controls. Furthermore, increased levels of miR-330-3p were associated with better response to treatment (diet vs. insulin), with lower levels associated with exogenous insulin requirement. We observed miR-330-3p to be significantly related to the percentage of caesarean deliveries, with miR-330-3p expression significantly higher in spontaneously delivered GDM patients. We report this strong novel association of circulating miR-330-3p with risk of primary caesarean delivery as a pregnancy outcome linked with poor maternal glycaemic control, strengthening the growing body of evidence for roles of diabetes-associated miRNAs in glucose homeostasis and adaptation to the complex changes related to pregnancy.

23 June 2015 in Genes
Verified
Journal Article
Open access
PDF file
SBSiobhán Bacon
Siobhán Bacon
BEBritta Engelbrecht
Britta Engelbrecht
JSJasmin Schmid
Jasmin Schmid
SPShona L Pfeiffer
Shona L Pfeiffer
RGRoss Gallagher
Ross Gallagher
MBMaria M. Byrne
Maria M. Byrne
MicroRNA (miRNA) are a class of non-coding, 19–25 nucleotide RNA critical for network-level regulation of gene expression. miRNA serve as paracrine signaling molecules. Using an unbiased array approach, we previously identified elevated levels of miR-224 and miR-103 to be associated with a monogenic form of diabetes; HNF1A-MODY. miR-224 is a novel miRNA in the field of diabetes. We sought to explore the role of miR-224 as a potential biomarker in diabetes, and whether such diabetes-associated-miRNA can also be detected in the urine of patients. Absolute levels of miR-224 and miR-103 were determined in the urine of n = 144 individuals including carriers of a HNF1A mutation, participants with type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and normal controls. Expression levels were correlated with clinical and biochemical parameters. miR-224 was significantly elevated in the urine of carriers of a HNF1A mutation and participants with T1DM. miR-103 was highly expressed in urine across all diabetes cohorts when compared to controls. For both miR-224 and-103, we found a significant correlation between serum and urine levels (p < 0.01). We demonstrate that miRNA can be readily detected in the urine independent of clinical indices of renal dysfunction. We surmise that the differential expression levels of miR-224 in both HNF1A-MODY mutation carriers and T1DM may be an attempt to compensate for beta-cell demise.